logo
'We're not giving up or giving in just yet,' says Healthwatch York manager

'We're not giving up or giving in just yet,' says Healthwatch York manager

Yahooa day ago
Following the government's announcement that the Healthwatch Network is to close, Siân Balsom, manager of Healthwatch York, has called on local and national leaders to rethink the proposals.
Press readers will already know the government has decided to abolish Healthwatch England and the network of local Healthwatch organisations. Truth be told, here at Healthwatch York, my small team and I are all still reeling from the news. But we're not giving up or giving in just yet.
Healthwatch York started in April 2013. Our role has always been clear to us – putting people at the heart of health and social care. Because the best people to shape services are those using them or, in too many cases, struggling to.
Across England, local Healthwatch organisations have played a vital role in raising patient concerns. We shine a light on service failures. We drive improvements through honest, evidence-based reporting.
Here in York, we have supported people to navigate complex systems and access the help they need. We've published guides to mental health and wellbeing support and dementia support. We've challenged gaps in mental health support both when our mental health hospital was closed at short notice and when we heard ongoing concerns about crisis care. We've worked to improve access to GP services. We've independently evaluated the changes to the adult ADHD and autism pathway. We've taken the concerns of deaf people to the heart of the NHS, helping shape the Accessible Information Standard. We've worked with the universities in our city to make sure more York voices are heard in research.
These achievements were possible because you trusted us to speak up on your behalf. Not as part of the system but as a critical friend holding it to account.
We have a seat at the table – attending the Health and Wellbeing Board and other key strategic meetings. But we've always known this isn't our seat – it belongs to each and every one of you, and we use everything we hear every time we take up that seat. Our independence is what enables us to speak both with authority and with integrity. Your voices are what gives our independence real power. We never forget the responsibility we carry to make sure you are heard.
We've been told our roles will be absorbed into local authorities and integrated care boards. Our role in listening to people and gathering feedback will be replaced by the NHS app. We have serious concerns about those voices that will never be heard in such a system. Those who don't have smartphones, or the data to use them. Those living with health conditions that mean regular hospital stays are inevitable, and fear speaking out will impact their long-term care. Those who feel they are fighting the system already and have lost faith in its ability to change. Those who just want to tell their story, in their own words and their own time. We know this matters, because people frequently let us know that in telling us it is the first time this happens for them.
Having read the NHS 10-year plan and Penny Dash's second review of patient safety, there is real concern they simply don't understand what we do. We've been described as 'ventriloquists' and 'checkers' in a system that needs more doers. We do not recognise this description of our work. We ARE doers. We're out and about week in, week out, visiting care homes, local libraries, sitting down with carers groups and disabled people's organisations, community groups and local charities. We work closely with our voluntary sector partners to amplify the voices of those least heard in health and care. And we choose our priorities based on what you tell us every day – with more than 160 people in York speaking to us in June 2025 alone.
We believe the proposed changes are a mistake. We urge local and national leaders to reflect on what will be lost if Healthwatch is stripped of its independence. An effective health and social care system must include a strong, visible, and impartial patient voice, one that listens without fear or favour, and speaks up without interference.
Despite the announcement, for us it is business as usual. We will continue at least until new legislation confirms the abolition and this is not expected until 2026. Your voices, your experiences, helping you access the help you need – these remain our priority. Email us at healthwatch@yorkcvs.org.uk or phone: 01904 621133.
If like us you think independent voice matters, and you want to raise your concerns, please contact your local MP.
We also expect to be sharing a petition alongside our Healthwatch network colleagues shortly.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report
DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report

Yahoo

time21 minutes ago

  • Yahoo

DaVita Reveals Its Developments Towards ESG Goals in Its Community Care Report

DaVita Inc. (NYSE:DVA) is one of the . On June 18, DaVita Inc. (NYSE:DVA) released its Community Care report, highlighting its long-standing commitment to corporate citizenship and development towards ESG goals for 2025. DaVita Inc. posted its major developments in 2024. In 2020, the company announced broadened ESG goals and has since reported progress against its five strategic focus areas, including Patient Care, Team Engagement, Environmental Stewardship, Healthy Communities, and Leading with Integrity and Accountability. The company's 100% global operations are on track to be matched by renewable energy purchases by 2025. Moreover, over 8,200 DaVita patients received a kidney transplant in 2024, the company's highest number of annual transplants to date. Chinnapong/ 'This year, we're reflecting on 25 years of patient care and progress made toward improving the health and vibrancy of the communities and people we serve. Looking ahead to the next 25 years, I'm excited about how we're positioned to build on these recent community health achievements to enhance the care experience for people around the world,' said Javier Rodriguez, chief executive officer for DaVita. DaVita Inc. (NYSE:DVA) is a healthcare provider focused on transforming care delivery to enhance the quality of life for patients worldwide. While we acknowledge the potential of DVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Physitrack PLC Adjusts its Financial Calendar - Earlier Publication of Q2 2025 Interim Report
Physitrack PLC Adjusts its Financial Calendar - Earlier Publication of Q2 2025 Interim Report

Yahoo

time30 minutes ago

  • Yahoo

Physitrack PLC Adjusts its Financial Calendar - Earlier Publication of Q2 2025 Interim Report

LONDON, GB / / July 14, 2025 / Physitrack PLC (STO:PTRK) - Physitrack PLC has adjusted its previously communicated financial calendar for 2025. The date for publication of the Q2 2025 interim report has been changed from 31 July 2025 to 24 July 2025. Updated financial calendar24 July 2025 - Interim report Q2 (1 Jan 2025 - 30 June 2025) - new date31 October 2025 - Interim report Q3 (1 Jan 2025 - 30 Sep 2025) 28 February 2026 - Interim Report Q4 and Year-end-report (1 Jan 2025 - 31 Dec 2025) The updated financial calendar is also available on the company's website: Enquiries regarding this announcement should be addressed to: Henrik Molin, CEO and co-founder, Physitrack.+44 208 133 9325ir@ About Physitrack Physitrack PLC, founded in 2012, is a global digital healthcare provider, focused on the B2B wellness and virtual-first care markets. With staff with 12 nationalities on four continents, customers in 17 time zones, and end users in 187 countries, Physitrack is a truly global company. The company has two business lines:1. Lifecare - SaaS platform tailored mainly to physiotherapy and musculoskeletal care, enabling practitioners to deliver clinical home exercises, education prescription, outcomes tracking, triaging and Telehealth.2. Wellness / Champion Health - SaaS platform for Employee Wellness and care powered by a combination of world-leading technology and wellness professionals based in the United Kingdom, Germany and the Nordics. Physitrack PLC is headquartered in London, United Kingdom, and listed on Nasdaq First North Premier Growth Market (PTRK). Visit us athttps:// (investor relations) (product marketing) About Champion Health Champion Health, a subsidiary of Physitrack Plc, is a leader in corporate wellness technology, providing an innovative platform that empowers businesses to support their employees' well-being through personalised wellness action plans and advanced analytics. Visit us athttps:// Attachments Physitrack PLC adjusts its financial calendar - earlier publication of Q2 2025 interim report SOURCE: Physitrack PLC View the original press release on ACCESS Newswire

Direct Challenge Safe for Penicillin Allergy in Pregnancy
Direct Challenge Safe for Penicillin Allergy in Pregnancy

Medscape

time37 minutes ago

  • Medscape

Direct Challenge Safe for Penicillin Allergy in Pregnancy

TOPLINE: In low-risk pregnant women with penicillin allergy, direct challenges with amoxicillin were as safe as penicillin skin testing while offering shorter completion times at a lower cost. METHODOLOGY: Researchers conducted a randomized trial that included 144 pregnant women (median age, 29 years) who were referred to the Rochester Regional Health allergy/immunology practice for routine penicillin allergy evaluation from April 2022 through September 2024. Patients were randomly assigned to undergo penicillin skin testing or a direct challenge. For the direct challenge, patients received oral amoxicillin 40 mg and were monitored for 30 minutes. If they did not react to this initial dose, they received 400 mg and were monitored for 30 minutes more. TAKEAWAY: Overall, 93.2% of women who underwent penicillin skin testing had a negative evaluation for penicillin allergy compared with 100% of women who underwent direct challenge. Direct challenges had a median completion time of 65 minutes and cost $422.61 each, whereas penicillin skin tests took a median of 75 minutes and cost $685.36 each. No participants in either group required medical treatment or epinephrine for reactions. Hospital length of stay postdelivery was not significantly different between the groups. IN PRACTICE: 'Although patients and healthcare professionals may be concerned about the risk of an adverse reaction with a [penicillin] allergy evaluation in pregnancy, particularly a [direct challenge], our study supports the safety of this approach in pregnant women in all trimesters,' the authors of the study wrote. SOURCE: Sara Patrawala, MD, with the University of Rochester School of Medicine and Dentistry, Rochester, New York, was the corresponding author of the study, which was published online on July 9 in The Journal of Allergy and Clinical Immunology: In Practice. LIMITATIONS: The study had a relatively small sample size and was conducted at a single site. DISCLOSURES: Two authors reported serving on speakers bureaus for pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store